QTRX — Quanterix Corp

Nasdaq · Unknown · Unknown · CIK 1503274 ·
Last close
$2.68
Market Cap
$126.24M
52W High
$6.67
52W Low
$2.39
ADV30
1,336,971
Next earnings
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 36,415,000 15,566,000 -21,527,000 -17,541,000 366,672,000 36,182,000 84,533,000
Dec 2025 43,777,000 19,960,000 -23,868,000 -23,117,000 418,766,000 29,839,000 123,036,000
Sep 2025 40,150,000 17,123,000 -30,151,000 -33,517,000 444,140,000 38,298,000 129,606,000
Jun 2025 24,454,000 11,278,000 -29,430,000 -30,013,000 375,609,000 132,896,000 83,151,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-77,236,000
Investing CF
$50,231,000
Financing CF
$-708,000
CapEx
$-3,122,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.52
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-577,231,000
Inventory
$54,763,000
Receivables
$29,972,000
ST Investments
$88,393,000
EBIT TTM
$-109,815,000
Pretax Income TTM
$-112,272,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$144,979,008
EBITDA
$-63,673,000
Free Cash Flow
$-21,983,500
Enterprise Value
$62,786,088
Total Cash
$99,265,000
Total Debt
$35,336,000
Shares Out
47,105,981
Trailing EPS
$-2.35
Book Value
$6.00
ROE
-34.8%
ROA
-13.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 138,654,000 -109,815,000 -107,150,000 418,766,000 123,036,000 -77,236,000
Dec 2024 135,436,000 -52,616,000 -38,531,000 406,533,000 76,495,000 -35,164,000
Dec 2023 121,139,000 -44,663,000 -28,354,000 428,567,000 78,609,000 -18,849,000
Dec 2022 104,952,000 -74,708,000 -99,574,000 433,582,000 75,650,000 -48,611,000

TTM Snapshot

Revenues TTM
$67,372,000
NetIncome TTM
$-15,069,000
OpCashFlow TTM
$0
Assets (Latest)
$406,533,000
Forward EPS
$-1.36

News headlines (Yahoo Finance, 1h cache)

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-26 20:01 · Yahoo
Quanterix Announces Planned Transition of Chief Financial Officer
2026-05-12 20:01 · Yahoo
Quanterix (QTRX) Q1 2026 Earnings Transcript
2026-05-07 14:44 · Yahoo
Quanterix Q1 Earnings Call Highlights
2026-05-07 04:08 · Yahoo
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 21:25 · Yahoo
Quanterix Releases Financial Results for the First Quarter of 2026
2026-05-06 20:01 · Yahoo
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
2026-05-06 12:00 · Yahoo
How The Quanterix (QTRX) Story Is Shifting After The Latest Fair Value Reset
2026-05-03 02:14 · Yahoo
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
2026-04-24 12:33 · Yahoo
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
2026-04-17 12:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.